Accuray CyberKnife® Robotic Radiotherapy Platform is Superior to Conventional Linear Accelerators in Reducing Incidence of Bladder Side Effects in Prostate Cancer Patients

SUNNYVALE, Calif.: SUNNYVALE, Calif., Sept. 14, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that data from the PACE – Prostate Advances in Comparative Evidence – trial indicate the company's CyberKnife® robotic radiotherapy platform is superior to conventional linear accelerators in reducing the incidence of late grade two or...

Click to view original post